3,097 Shares in AbbVie Inc. $ABBV Purchased by Providence First Trust Co

Providence First Trust Co acquired a new position in AbbVie Inc. (NYSE:ABBV) in the 4th quarter, HoldingsChannel reports. The fund acquired 3,097 shares of the company’s stock, valued at approximately $708,000.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in AbbVie by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Legal & General Group Plc boosted its stake in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP grew its holdings in shares of AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Amundi increased its stake in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock worth $2,418,909,000 after buying an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after buying an additional 408,426 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

ABBV has been the subject of several research reports. Royal Bank Of Canada assumed coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Canaccord Genuity Group lifted their price target on shares of AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Thursday, April 30th. DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $252.90.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 beat and raised guidance spurred a rally: AbbVie reported stronger?than?expected Q1 results and lifted 2026 guidance, which pushed the stock higher in early May as investors reassessed growth prospects from Skyrizi, Rinvoq and the pipeline. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Analyst and retail attention following the quarter: Coverage from Zacks highlights the company as a top?searched/“trending” stock, reflecting elevated investor interest after the beat — attention that can amplify moves on earnings or guidance news. ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?
• Positive Sentiment: Dividend appeal remains strong: Multiple income?focused outlets continue to list AbbVie as a high?yield dividend candidate, supporting demand from dividend investors despite valuation considerations. Want to Collect a High Dividend Every Month? Invest in These 3 Stocks
• Neutral Sentiment: Positive clinical and real?world data showcased at DDW: AbbVie presented long?term and real?world evidence for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) in IBD, which supports the commercial outlook but will take time to materially change revenue trajectory. AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
• Neutral Sentiment: Industry tech/AI events mention AbbVie involvement: Participation in life?science AI forums signals digital investment but is unlikely to move near?term fundamentals. Zifo’s SiEE Boston Summit Charts New Roadmap for ‘Practical AI’ in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
• Negative Sentiment: Regulatory/manufacturing setback for a wrinkle treatment: The U.S. FDA declined to approve AbbVie’s wrinkle product over manufacturing concerns (reported April 23), a near?term headwind that can pressure sentiment and highlight execution risk on noncore franchises. US FDA declines to approve AbbVie’s wrinkle treatment due to manufacturing concerns (April 23)

AbbVie Price Performance

ABBV opened at $206.12 on Wednesday. The firm has a fifty day moving average price of $214.17 and a 200 day moving average price of $221.34. AbbVie Inc. has a 1 year low of $176.57 and a 1 year high of $244.81. The stock has a market cap of $364.46 billion, a P/E ratio of 101.54, a P/E/G ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 earnings per share. Equities analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s payout ratio is 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.